Editorial update — September 28, 2026. Revised by Averin Capital to replace dated cost projections and clarify how virtual care programs should be evaluated. The original publication date and author attribution are retained.
Virtual obesity-care companies face a demanding question: can they make appropriate treatment easier to access and sustain while demonstrating value to patients and the organizations paying for care?
A prescription is one part of that service. Assessment, follow-up, support, medication access, and coordination with other clinicians all shape whether a program works in practice.
Evaluate the whole program
The National Institute of Diabetes and Digestive and Kidney Diseases describes prescription weight-management medications as part of care that includes healthy eating and physical activity. It also notes that people may regain weight after stopping medication. These are reasons to evaluate ongoing support and continuity of care, rather than treating an initial prescription or short-term weight change as the full outcome.
Programs should be assessed on their own evidence: who enrolls, who remains engaged, what outcomes are measured, how adverse effects are addressed, and how results differ across patient groups. Comparisons should account for differences in populations and follow-up rather than relying on headline results.
Cost claims need a clear baseline
Lower pharmacy spending alone does not establish better care or lower total cost. Employers and health plans need to understand program fees, medication costs, utilization, retention, and the time horizon over which outcomes are measured. Claims about savings should make the comparison group and assumptions explicit.
Medication decisions belong within individualized clinical care. A business model that simply restricts access is a different proposition from one that demonstrates appropriate treatment, better support, and measurable value.
Where a durable company can emerge
We are interested in companies that reduce friction in care while developing credible evidence for their approach. That can include better coordination, practical adherence support, transparent measurement, and integration with a patient’s broader care team.
The opportunity is to build a service that patients and clinicians can rely on over time. The strongest investment case connects that service to demonstrated outcomes and sustainable economics.
Source for this update
NIDDK: Prescription Medications to Treat Overweight & Obesity
